<DOC>
	<DOCNO>NCT02575222</DOCNO>
	<brief_summary>This study evaluate use nivolumab surgery patient high-risk clear cell renal cell carcinoma eligible nephrectomy . Nivolumab antibody may help activate immune system block function inhibitory molecule , PD-1 .</brief_summary>
	<brief_title>Study Neoadjuvant Nivolumab Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : 1 . Confirmed nonmetastatic highrisk clear cell renal cell carcinoma ( T2aT4NanyM0 TanyN1M0 ) 2 . Schedule undergo either partial radical nephrectomy part treatment plan 3 . Patient agree tumor biopsy 4 . ECOG performance status 0 1 5 . Adequate organ marrow function define studyspecified laboratory test 6 . Must use acceptable form birth control study approximately 31 week posttreatment completion 7 . Willingness ability comply schedule visit , treatment plan , lab test study procedure Exclusion Criteria ( abbreviate ) : 1 . Other active malignancy within last 3 year ( exception skin , prostate , cervical , breast cancer ) 2 . Need urgent emergent nephrectomy relieve symptom 3 . Prior treatment RCC include surgery , radiation , thermoablation systemic therapy 4 . Surgery within 28 day start study treatment ( exception minor procedure ) 5 . Received live vaccine infectious disease within 28 day start study treatment 6 . Prior treatment antibody drug target Tcell costimulation immune checkpoint pathway ( antiPD1 , antiPDL1 , antiPDL2 , antiCTLA4 , etc ) 7 . Use immunosuppressive dos systemic medication within 14 day prior start study drug . 8 . Current use immunosuppressive agent 9 . History severe hypersensitivity reaction monoclonal antibody 10 . Current sign symptom severe progressive uncontrolled hepatic , hematologic , gastrointestinal , endocrine , pulmonary cardiac disease directly relate RCC 11 . Uncontrolled psychiatric illness/social situation would limit compliance study requirement . 12 . Active infection require therapy . 13 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 14 . Positive test Hepatitis B surface antigen Hepatitis C ribonucleic acid ( RNA ) . 15 . History autoimmune disease syndrome require systemic steroid immunosuppressant ( exception apply ) . 16 . Pulse oximetry &lt; 92 % room air 17 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>PD-1</keyword>
	<keyword>anti-PD-1</keyword>
	<keyword>antibody</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>RCC</keyword>
	<keyword>non-metastatic</keyword>
</DOC>